Considering the Side Effects of Drugmakers’ Money-Back Guarantees by KATIE THOMAS and CHARLES ORNSTEIN


By KATIE THOMAS and CHARLES ORNSTEIN

The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.

Published: July 9, 2017 at 08:00PM

from NYT Health http://ift.tt/2u07daw
via IFTTT

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s